Non-Hodgkin's B cell lymphoma (AIDS-lymphoma) is seen in greatly-elevated frequency in AIDS and HIV infection. In this proposal, studies to delineate immune system changes in HIV infection that are relevant to the development of AIDS-lymphoma are presented.
The specific aims are: l) to elucidate the mechanism by which IL6 enhances the resistance of lymphoblastoid B cells, or AIDS-lymphoma cells, to cytotoxic T lymphocyte- mediated lysis and apoptosis, by determining if IL6 modulates the expression or activity of cellular receptors (fas, TNF-receptor, CD4O) for apoptotic signals or of proto-oncogenes (p53 or bcl-2) involved in the regulation of apoptosis, 2) to confirm preliminary studies indicating that Hiv-i gp4l can induce monokine (IL6 and IL10) production, to determine if other immune cells bind and respond to gp41, and to identify the molecule on monocytes that interacts with HIV gp4l, and 3) to define immune- stimulatory factors that contribute to the greatly elevated levels of serum sCD23 seen in AIDS-lymphoma and/or to AIDS-lymphoma cell growth. The accomplishment of these specific aims will add valuable new information to our understanding of the role of immune dysfunction in the generation and growth of AIDS-associated lymphoma. While the dominant immune system dysfunction seen in AIDS is a severe functional and numerical CD4 T cell defect, various other immune system changes are seen, including a marked increase in B cell activation. The high frequency of B cell lymphoma seen in HIV infection may result from this chronic polyclonal B cell stimulation, which could increase the frequency of c-myc:Ig gene chromosomal translocations, resulting in B cell tumors. Also, loss of immunoregulatory control of EBV-activated lymphoblastoid B cells could contribute to AIDS-lymphoma: IL6 appears to allow such cells to escape growth control, by enhancing resistance to CTL- mediated killing. Studies described in this proposal will examine how HIV interacts with monocytes, resulting in the induction of IL6 production, the mechanisms by which IL6 acts as a viability-enhancing, apoptosis- inhibiting factor for EBV-transformed lymphoblastoid B cells and AIDS- lymphoma cells, as well as the role of B cell stimulatory factors (cytokines, cytokine receptors, and cell-surface stimulatory molecules), other than IL6, in AIDS-lymphoma cell growth. The realization of the specific aims will provide valuable information on the relationship between HIV-induced immune dysfunction and the development of AIDS-lymphoma. This information could form the foundation for future studies on the role of cytokines in AIDS-lymphoma, or could suggest new forms of treatment for AIDS-related diseases. Also, the realization of these specific aims could lead to new screening techniques able to detect AIDS-lymphoma earlier in the course of tumor development, allowing for earlier clinical intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA057152-04A1
Application #
2097910
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1992-04-03
Project End
1998-06-30
Budget Start
1995-08-16
Budget End
1996-06-30
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Bonavida, Benjamin (2014) RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-?B/Snail/YY1/RKIP resistance-driver loop. Crit Rev Oncog 19:431-45
Thapa, Dharma R; Hussain, Shehnaz K; Tran, Wen-Ching et al. (2014) Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J Acquir Immune Defic Syndr 66:229-37
Vendrame, Elena; Hussain, Shehnaz K; Breen, Elizabeth Crabb et al. (2014) Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 23:343-9
Widney, Daniel P; Olafsen, Tove; Wu, Anna M et al. (2013) Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7. PLoS One 8:e72414
Daniels-Wells, Tracy R; Helguera, Gustavo; Rodríguez, José A et al. (2013) Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro 27:220-31
Hussain, Shehnaz K; Zhu, Weiming; Chang, Shen-Chih et al. (2013) Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 22:295-307
Daniels, Tracy R; Bernabeu, Ezequiel; Rodríguez, José A et al. (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820:291-317
Daniels, Tracy R; Martínez-Maza, Otoniel; Penichet, Manuel L (2012) Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother 61:1535-46
Thapa, Dharma R; Bhatia, Kishor; Bream, Jay H et al. (2012) B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas. AIDS 26:1177-80
Daniels, Tracy R; Leuchter, Richard K; Quintero, Rafaela et al. (2012) Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother 61:991-1003

Showing the most recent 10 out of 49 publications